PLA2G7 and metabolic dysfunction-associated steatotic liver disease: Given that high Lp-PLA2 activity is a hallmark of metabolic-dysfunction-associated steatotic liver disease (MASLD), we aimed to investigate whether it contributes additional CVD risks when MASLD coexists with T2DM.